logo

Zynerba Pharmaceuticals, Inc. (ZYNE)



Trade ZYNE now with
  Date
  Headline
2/26/2019 7:25:11 AM Zynerba Pharma Gets New U.S. Patent For Fragile X Syndrome With Cannabidiol
1/22/2019 8:47:24 AM SCYNEXIS Appointms Armando Anido To Its Board
11/8/2018 6:55:16 AM Zynerba Pharma Q3 Loss Per Share $0.47 Vs Loss $0.63 Last Year
8/2/2018 6:54:42 AM Zynerba Q2 Net Loss $12.0 Mln Or $0.89/Shr
7/20/2018 9:11:31 AM Zynerba Pharma Prices Underwritten Public Offering Of 4.06 Mln Shares At $8.00/shr
7/19/2018 4:08:24 PM Zynerba Pharmaceuticals Announces Proposed Public Offering Of Common Stock
7/12/2018 7:33:40 AM Zynerba Pharma Announces New FAB-C Phase 2 Open-Label Data In Patients With Fragile X Syndrome
7/9/2018 6:56:27 AM Zynerba Begins CONNECT-FX, A Pivotal Clinical Trial Of ZYN002 In Fragile X Syndrome
7/5/2018 4:23:22 PM Zynerba's Marijuana Flop
7/5/2018 1:09:04 PM Zynerba Shares Fall After Trial Of Cannabis-based Skin Patch Fails To Meet Goals
7/5/2018 7:31:53 AM Zynerba Pharma Announces Top Line Results From ZYN001 THC-Prodrug Patch Phase 1 Study
5/8/2018 7:38:25 AM Zynerba Pharma Posts Q1 Net Loss Of $12.31 Mln Or $0.91/share
4/25/2018 7:21:27 AM Zynerba Announces Twelve Month ZYN002 Data From STAR 2 Study